Mo (Mohammad) Tabrizi PhD
Mo (Mohammad) Tabrizi PhD joined Juvena Therapeutics in 2022, bringing over 25 years’ experience in basic research, integrative pharmacology, translational sciences, and development of protein-based biologics. Prior to Joining Juvena Therapeutics, Dr. Tabrizi served in positions with increasing responsibilities at Large companies such as Merck Research Laboratories, AstraZeneca/Medimmune, and biotech companies such as Soteria Biotherapeutics, Acendis pharma and Abgenix. His product development experience spans many therapeutic areas including oncology, immune-oncology, and inflammatory diseases.
He has been an author or co-inventor on more than 50 original papers, reviews articles, published books and patents. Dr. Tabrizi has been an invited speaker to numerous national and international conferences. Dr. Tabrizi received his bachelor’s degree in Pharmacy from University of Houston (Summa Cum Laude) and his PhD from University at Buffalo, State University of New York (SUNY) in Pharmaceutical Sciences. He completed a postdoctoral training in pharmacology at University of New York at Buffalo (SUNY) with a focus on therapeutics.
Learn more about Mohammad